September 25, 2017 4:52 AM ET


Company Overview of Actavis Pharma, Inc.

Company Overview

Actavis Pharma, Inc. develops, manufactures, and markets generic pharmaceutical products. It offers solid dosage and sterile dosage generic products. The company was formerly known as Schein Pharmaceutical, Inc. The company was founded in 1931 and is based in Parsippany, New Jersey. As of August 28, 2000, Actavis Pharma, Inc. operates as a subsidiary of Allergan plc.

400 Interpace Parkway

Morris Corporate Center III

Parsippany, NJ 07054

United States

Founded in 1931

1,325 Employees





Key Executives for Actavis Pharma, Inc.

Chairman and Chief Executive Officer
Age: 71
Senior Vice President of Strategic Development
Age: 64
Senior Vice President of Technical Operations
Age: 71
Senior Vice President of Corporate Quality Assurance
Age: 68
Other Professional
Compensation as of Fiscal Year 2017.

Actavis Pharma, Inc. Key Developments

Orexo AB (publ.) Files Patent Infringement Action in United States District Court for the District of Delaware Against Actavis Elizabeth LLC, Actavis Pharma, Inc., and Teva

Orexo AB (publ.) announced that it has filed a patent infringement action in United States District Court for the District of Delaware against Actavis Elizabeth LLC, Actavis Pharma Inc., and Teva. Orexo alleges that Actavis's generic versions of Suboxone and Subutex tablets infringe Orexo's U.S. Patent No. 8,454,996 (the '996 patent). On November 15, 2016, the Delaware District Court held Orexo's '996 patent (which expires in September 2019) valid and infringed by Actavis's generic versions of Zubsolv. Actavis did not appeal the district court's decision regarding the '996 patent. Orexo believes Actavis's generic versions of Suboxone and Subutex tablets, which like Zubsolv include buprenorphine as an active ingredient, also infringe Orexo's '996 patent. Actavis's generic version of Suboxone was approved by the FDA in February 2013 and their generic version of Subutex in February 2015. Orexo is seeking compensation for damages caused by Actavis's infringement of the '996 patent since approval of these two products.

VIVUS, Inc. Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation

VIVUS, Inc. announced that the United States District Court for the District of New Jersey has issued a claim construction (Markman) ruling governing patent litigation brought by VIVUS against Actavis Laboratories FL, Inc., Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis, and Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., collectively referred to as Teva. The lawsuits were filed in response to Abbreviated New Drug Applications, or ANDAs, filed by Actavis and Teva. In these applications, Actavis and Teva seek to market and sell a generic version of the currently approved doses of Qsymia® (phentermine and topiramate extended-release) capsules CIV prior to the expiration of U.S. Patents listed in the FDA's approved drug products with Therapeutic Equivalence Evaluations, or the Orange Book. There are ten (10) VIVUS patents asserted in the litigation, the last of which expires in 2029. VIVUS, Inc. filed the lawsuits on the basis that Actavis' and Teva's proposed generic products infringe the VIVUS patents. In a Markman ruling, also known as a claim construction ruling, the Court determines the meaning of disputed patent claim terms at issue in patent litigation. In a July 20, 2016 Markman ruling, Judge Stanley R. Chesler adopted VIVUS' proposed constructions for all but one of the disputed claim terms and adopted a compromise construction that was acceptable to VIVUS for the final claim term. The next phase of the ongoing litigation with Actavis will be expert discovery. The Teva case remains in fact discovery. No trial date has been scheduled in either case.

Shire Wins Patent Trial against Watson Concerning LIALDA

Shire plc and its subsidiary, Shire Development LLC, announced that the United States District Court for Southern Florida has upheld its patent for LIALDA® (mesalamine) delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. The decision follows litigation by Shire against Watson Pharmaceuticals Inc., Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and Watson Laboratories, Inc. in connection with their Abbreviated New Drug Application (ANDA) for a generic version of LIALDA.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Actavis Pharma, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at